Keros Therapeutics (Nasdaq:KROS) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

KROS Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Keros Therapeutics, Inc., Amerika Birleşik Devletleri'nde dönüştürücü büyüme faktörü-beta protein ailesinin işlevsiz sinyalizasyonuyla bağlantılı bozuklukları olan hastalar için yeni terapötikler geliştirmekte ve ticarileştirmektedir.

Şirket hakkında

KROS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 71.43% oranında artması öngörülüyor

Analistler hisse senedi fiyatının 52% oranında artacağı konusunda hemfikir

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $271K )

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Keros Therapeutics, Inc. Rakipler

Inhibrx

NasdaqGM:INBX

US$1.8b

Syndax Pharmaceuticals

NasdaqGS:SNDX

US$1.6b

Viridian Therapeutics

NasdaqCM:VRDN

US$1.8b

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Keros Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$60.90
52 Haftanın En Yüksek Seviyesi	US$73.00
52 Haftanın En Düşük Seviyesi	US$27.02
Beta	1.23
11 Aylık Değişim	15.98%
3 Aylık Değişim	46.11%
1 Yıllık Değişim	96.64%
33 Yıllık Değişim	64.82%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	203.29%

Son Haberler & Güncellemeler

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Recent updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27

Keros Therapeutics prices equity offering at $50

Nov 13

Hissedar Getirileri

	KROS	US Biotechs	US Pazar
7D	7.9%	-0.5%	0.3%
1Y	96.6%	18.0%	32.4%

Getiri vs. Endüstri: KROS geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: KROS geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is KROS's price volatile compared to industry and market?
KROS volatility
KROS Average Weekly Movement	7.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: KROS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: KROS 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	149	Jas Seehra	www.kerostx.com

Klinik aşamada bir biyofarmasötik şirketi olan Keros Therapeutics, Inc. ABD'de dönüştürücü büyüme faktörü-beta protein ailesinin işlevsiz sinyalizasyonuyla bağlantılı bozuklukları olan hastalar için yeni terapötikler geliştirmekte ve ticarileştirmektedir. Şirketin öncü ürün adayı, miyelodisplastik sendromlu hastalarda ve miyelofibrozisli hastalarda anemi ve trombositopeni dahil olmak üzere düşük kan hücresi sayılarının veya sitopenilerin tedavisi için geliştirilmekte olan KER-050'dir. Ayrıca, pulmoner arteriyel hipertansiyon ve kardiyovasküler bozuklukları tedavi etmek için Faz II klinik çalışmasında olan KER-012'yi ve obezite ve nöromüsküler hastalıkların tedavisi için Faz I klinik çalışmasında olan KER-065'i geliştirmektedir.

Keros Therapeutics, Inc. Temel Bilgiler Özeti

Keros Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
KROS temel i̇stati̇sti̇kler
Piyasa değeri	US$2.29b
Kazançlar(TTM)	-US$168.05m
Gelir(TTM)	US$271.00k

8,432x

P/S Oranı

-13.6x

F/K Oranı

KROS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
KROS gelir tablosu (TTM)
Gelir	US$271.00k
Gelir Maliyeti	US$150.41m
Brüt Kâr	-US$150.13m
Diğer Giderler	US$17.92m
Kazançlar	-US$168.05m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.48
Brüt Marj	-55,400.37%
Net Kâr Marjı	-62,012.55%
Borç/Özkaynak Oranı	0%

KROS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

KROS Stoklara Genel Bakış

Ödüller

Risk Analizi

Keros Therapeutics, Inc. Rakipler

NasdaqGM:INBX

US$1.8b

NasdaqGS:SNDX

US$1.6b

NasdaqCM:VRDN

US$1.8b

NasdaqGM:CRSP

US$4.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Recent updates

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$158k worth of stock

Chief Scientific Officer exercised options and sold US$133k worth of stock

Keros Therapeutics, Inc. Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

Chief Scientific Officer exercised options and sold US$527k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Consultant Claudia Ordonez has left the company

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Microcap Value Index

Keros Therapeutics, Inc. Announces Preliminary Results from Its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

Chief Scientific Officer notifies of intention to sell stock

Keros Therapeutics, Inc. Presents Data from the ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of KER-012

Chief Scientific Officer exercised options and sold US$132k worth of stock